COMPASS: Genomic Profiling Could Guide Treatment in Advanced Pancreatic Cancer
As part of our coverage of the 2018 Gastrointestinal Cancers Symposium, held January 18–20 in San Francisco, we are speaking with Kyaw L. Aung, MBBS, PhD, a clinical fellow at the Princess Margaret Cancer Centre in Toronto.
Dr. Aung presented updated data from the COMPASS trial which used whole-genome sequencing and RNA sequencing to analyze the tumors of patients with advanced pancreatic ductal adenocarcinoma to identify possible first-line treatments.
Cancer Network: First, can you tell us about the design of the COMPASS study? What is unique about the study, either as a pancreatic cancer study or as a cancer trial in general?
Dr. Aung: The COMPASS study was designed to acquire a fresh tumor biopsy from patients with advanced pancreatic cancer, and both locally advanced and metastatic patients were included in this trial. Read more . . .